350 related articles for article (PubMed ID: 34632904)
1. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C
Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904
[TBL] [Abstract][Full Text] [Related]
2. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
Cárdenas-Soto K; Dominguez XH; Cortes G; Tsai F; Saniger MDM; Guraieb-Chahin P; Torres-Ocatvo B; Gibbons C; Kelly JW; Freeman R; González-Duarte A
J Peripher Nerv Syst; 2024 Jun; 29(2):221-231. PubMed ID: 38706223
[TBL] [Abstract][Full Text] [Related]
4. Correlation between a commercial electrophysiological test of sudomotor function and intraepidermal nerve fiber density in hereditary transthyretin amyloidosis.
Masuda T; Misumi Y; Nomura T; Yamakawa S; Tasaki M; Obayashi K; Ando Y; Ueda M
Muscle Nerve; 2024 Jan; 69(1):99-102. PubMed ID: 37960924
[TBL] [Abstract][Full Text] [Related]
5. Quantitative sensory testing and skin biopsy findings in late-onset ATTRv presymptomatic carriers: Relationships with predicted time of disease onset (PADO).
Leonardi L; Costanzo R; Forcina F; Morino S; Antonini G; Salvetti M; Luigetti M; Romano A; Primiano G; Guglielmino V; Fionda L; Garibaldi M; Lauletta A; Rossini E; Tufano L; Ceccanti M; Esposito N; Falco P; di Pietro G; Truini A; Galosi E
J Peripher Nerv Syst; 2023 Sep; 28(3):390-397. PubMed ID: 37535421
[TBL] [Abstract][Full Text] [Related]
6. Transthyretin amyloidosis: Putting myopathy on the map.
Pinto MV; Milone M; Mauermann ML; Dyck PJB; Alhammad R; McPhail ED; Grogan M; Liewluck T
Muscle Nerve; 2020 Jan; 61(1):95-100. PubMed ID: 31587306
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Barroso FA; Coelho T; Dispenzieri A; Conceição I; Waddington-Cruz M; Wixner J; Maurer MS; Rapezzi C; Planté-Bordeneuve V; Kristen AV; González-Duarte A; Chapman D; Stewart M; Amass L;
Amyloid; 2022 Sep; 29(3):175-183. PubMed ID: 35451899
[TBL] [Abstract][Full Text] [Related]
8. Targeted sequencing of selected functional genes in patients with wild-type transthyretin amyloidosis.
Moreno-Gázquez I; Pérez-Palacios R; Abengochea-Quílez L; Lahuerta Pueyo C; Roteta Unceta Barrenechea A; Andrés Gracia A; Aibar Arregui MA; Menao Guillén S
BMC Res Notes; 2023 Oct; 16(1):249. PubMed ID: 37784196
[TBL] [Abstract][Full Text] [Related]
9. Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.
Beauvais D; Labeyrie C; Cauquil C; Francou B; Eliahou L; Not A; Echaniz-Laguna A; Adam C; Slama MS; Benmalek A; Leonardi L; Rouzet F; Adams D; Algalarrondo V; Beaudonnet G
J Neurol Neurosurg Psychiatry; 2024 May; 95(6):489-499. PubMed ID: 37875336
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
[TBL] [Abstract][Full Text] [Related]
11. Ophthalmological involvement in wild-type transthyretin amyloidosis: A multimodal imaging study.
Frizziero L; Salvalaggio A; Cosmo E; Cipriani A; Midena E; Briani C
J Peripher Nerv Syst; 2023 Dec; 28(4):586-596. PubMed ID: 37552555
[TBL] [Abstract][Full Text] [Related]
12. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
Razvi Y; Ioannou A; Patel RK; Chacko L; Karia N; Riefolo M; Porcari A; Rauf MU; Starr N; Ganesananthan S; Blakeney I; Kaza N; Filisetti S; Bolhuis RE; Rowczenio D; Gilbertson J; Hutt D; Mahmood S; Lachmann HJ; Wechalekar AD; Kotecha T; Knight DS; Coghlan JG; Petrie A; Whelan CJ; Venneri L; Martinez-Naharro A; Hawkins P; Fontana M; Gillmore JD
Eur J Heart Fail; 2024 Feb; 26(2):383-393. PubMed ID: 37953725
[TBL] [Abstract][Full Text] [Related]
13. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.
Leonardi L; Adam C; Beaudonnet G; Beauvais D; Cauquil C; Not A; Morassi O; Benmalek A; Trassard O; Echaniz-Laguna A; Adams D; Labeyrie C
Eur J Neurol; 2022 May; 29(5):1477-1487. PubMed ID: 35100482
[TBL] [Abstract][Full Text] [Related]
14. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
Lyng CS; Gude E; Hodt A; Knudsen EC
Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
[TBL] [Abstract][Full Text] [Related]
15. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.
Nativi-Nicolau J; Judge DP; Hoffman JE; Gundapaneni B; Keohane D; Sultan MB; Grogan M
ESC Heart Fail; 2021 Oct; 8(5):3875-3884. PubMed ID: 34432383
[TBL] [Abstract][Full Text] [Related]
16. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
Ungericht M; Wanschitz J; Kroiss AS; Röcken C; Schuetz T; Messner M; Zaruba MM; Loescher WN; Poelzl G
J Nucl Cardiol; 2023 Aug; 30(4):1420-1426. PubMed ID: 35581484
[TBL] [Abstract][Full Text] [Related]
17. The functional and structural evaluation of small fibers in asymptomatic carriers of TTR p.Val50Met (Val30Met) mutation.
Bekircan-Kurt CE; Yilmaz E; Arslan D; Yildiz FG; Dikmetas Ö; Ergul-Ulger Z; Kocabeyoglu S; Irkec M; Hekimsoy V; Tokgozoglu L; Tan E; Erdem-Ozdamar S
Neuromuscul Disord; 2022 Jan; 32(1):50-56. PubMed ID: 34980537
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
19. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
[TBL] [Abstract][Full Text] [Related]
20. Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center's experience.
Živković SA; Lacomis D; Soman P
Front Cardiovasc Med; 2024; 11():1345608. PubMed ID: 38410247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
